» Articles » PMID: 24073301

Hepatitis C Genotype 6: A Concise Review and Response-guided Therapy Proposal

Overview
Journal World J Hepatol
Specialty Gastroenterology
Date 2013 Sep 28
PMID 24073301
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis C genotype 6 is endemic in Southeast Asia [prevalence varies between 10%-60% among all hepatitis C virus (HCV) infection], as well as also sporadically reported outside the area among immigrations. The diagnosis of HCV genotype can be inaccurate with earlier methods of genotyping due to identical 5'-UTR between genotype 6 and 1b, hence the newer genotyping methods with core sequencing are preferred. Risk factors and clinical course of HCV genotype 6 do not differ considerably from other genotypes. Treatment outcome of HCV genotype 6 with a combination of pegylated interferon and ribavirin is superior to genotype 1, and nearly comparable to genotype 3, with expected sustained virological response (SVR) rates of 60%-90%. Emerging data suggests that a shorter course 24-wk treatment is equally effective as a standard 48-wk treatment, particularly for those patients who attained undetectable HCV RNA at week 4 (RVR). In addition, baseline and on-treatment predictors of response used for other HCV genotypes appear effective with genotype 6. Although some pan-genotypic direct-acting antivirals have completed phase II/III studies (sofosbuvir and simeprevir) with clinical benefit demonstrated in small number of patients with genotype 6, broad availability of these agents in Southeast Asia may not be expected in the near future. While awaiting the newer therapy, response-guided therapy seems appropriate for patients with HCV genotype 6. Patients with RVR (representing > 70% of patients) are suitable for 24-wk treatment with expected SVR rates > 80%. Patients without RVR and/or those with poor response predictors may benefit from 48 wk of therapy, and a detectable HCV RNA at week 12 (with no early virological response) serves as a stopping rule. This treatment scheme is likely to have a major economic impact on HCV therapy, particularly in Southeast Asia, wherein treatment can be truncated securely in the majority of patients with HCV genotype 6.

Citing Articles

Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study.

Ji F, Tran S, Ogawa E, Huang C, Suzuki T, Wong Y J Clin Transl Hepatol. 2024; 12(7):646-658.

PMID: 38993510 PMC: 11233980. DOI: 10.14218/JCTH.2024.00089.


Determination of hepatitis C virus subtype prevalent in Sindh, Pakistan: a phylogenetic analysis.

Farooq S, Faiz S, Wahab A, Choudhary M Sci Rep. 2024; 14(1):11159.

PMID: 38750152 PMC: 11096182. DOI: 10.1038/s41598-024-59342-7.


Determination of Risk Factors Associated with the Failure of 12 Weeks of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Prospective Study.

Nguyen Thi Thu P, Ngo Thi Quynh M, Pham Van L, Nguyen Van H, Thanh H Biomed Res Int. 2022; 2022:6054677.

PMID: 35572735 PMC: 9106452. DOI: 10.1155/2022/6054677.


Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.

Sun H, Cheng C, Lin C, Yang C, Lee N, Liou B World J Gastroenterol. 2022; 28(11):1172-1183.

PMID: 35431505 PMC: 8985481. DOI: 10.3748/wjg.v28.i11.1172.


Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam.

Shikuma C, Le T, Phuong T, Chew G, Nguyen V, Vo T AIDS Res Hum Retroviruses. 2021; 38(6):441-450.

PMID: 34861767 PMC: 10027344. DOI: 10.1089/AID.2021.0076.


References
1.
Lwin A, Shinji T, Myo Khin , Win N, Obika M, Okada S . Hepatitis C virus genotype distribution in Myanmar: Predominance of genotype 6 and existence of new genotype 6 subtype. Hepatol Res. 2007; 37(5):337-45. DOI: 10.1111/j.1872-034X.2007.00053.x. View

2.
. Hepatitis C--global prevalence (update). Wkly Epidemiol Rec. 2000; 74(49):425-7. View

3.
Prescott L, Simmonds P, Lai C, Chan N, Pike I, Yap P . Detection and clinical features of hepatitis C virus type 6 infections in blood donors from Hong Kong. J Med Virol. 1996; 50(2):168-75. DOI: 10.1002/(SICI)1096-9071(199610)50:2<168::AID-JMV10>3.0.CO;2-I. View

4.
Jutavijittum P, Jiviriyawat Y, Yousukh A, Pantip C, Maneekarn N, Toriyama K . Genotypic distribution of hepatitis C virus in voluntary blood donors of northern Thailand. Southeast Asian J Trop Med Public Health. 2009; 40(3):471-9. View

5.
Nguyen M, Trinh H, Garcia R, Nguyen G, Lam K, Keeffe E . Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol. 2008; 103(5):1131-5. DOI: 10.1111/j.1572-0241.2008.01793.x. View